Shattuck Labs (STTK) AI Stock Analysis

• Market Cap: $199.33M
• Dividend Yield: N/A
• Average Volume (3M): 550.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.14
• Revenue Growth: -84.46%
• EPS Growth: 33.32%
• Country: US
• Employees: 44
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.14
• Shares Outstanding: 63,279,842
• 10 Day Avg. Volume: 553,172
• 30 Day Avg. Volume: 550,087
• PEG Ratio: 0.03
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 10.74
• P/FCF Ratio: -1.01
• Enterprise Value/Market Cap: -0.04
• Enterprise Value/Revenue: -7.11
• Enterprise Value/Gross Profit: 8.22
• Enterprise Value/Ebitda: 0.13
• 1Y Price Target: $4.00
• Price Target Upside: 27.39% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $3.50 ▲(11.46% Upside)

The overall stock score is primarily influenced by strong technical momentum, which is offset by poor financial performance and unattractive valuation. The stock's bullish trend is notable, but financial instability and lack of profitability present significant risks. Investors should be cautious of the overbought technical indicators and the company's reliance on external financing.

Positive Factors

Strategic Partnerships

Strategic partnerships provide Shattuck Labs with financial growth opportunities and access to broader markets, enhancing its competitive position.

Proprietary Technology

The proprietary technology positions Shattuck Labs as an innovator in immune cell therapies, offering potential for unique product development and market differentiation.

Strong Cash Position

A strong cash position provides Shattuck Labs with the liquidity needed to fund R&D and operational activities, supporting long-term strategic initiatives.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in product commercialization and market penetration, potentially impacting long-term financial sustainability.

Negative Profitability

Persistent negative profitability highlights operational inefficiencies and challenges in achieving cost-effective operations, impacting long-term viability.

Reliance on External Financing

Dependence on external financing for operations can lead to financial instability and limit strategic flexibility, posing risks to long-term growth.

Shattuck Labs Business Overview & Revenue Model

Company Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

How the Company Makes Money

Shattuck Labs generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies, which provide funding for research and development in exchange for rights to commercialize products developed from their technology. Additionally, the company may receive milestone payments as specific development targets are met during the clinical trial phases. Another key revenue stream could come from licensing agreements, where Shattuck allows other companies to use its proprietary technologies in their own drug development efforts. Sales of any successfully developed therapeutics, once they are approved by regulatory bodies, will also contribute to the company’s earnings. Strategic collaborations with industry leaders enhance the company’s financial growth and provide access to broader markets.

Shattuck Labs Financial Statement Overview

Summary

Shattuck Labs faces significant financial challenges with declining revenues, negative profitability, and operational inefficiencies. While the company maintains a strong cash position, it relies heavily on external financing. The biotechnology industry often involves high R&D costs, contributing to losses. Continued focus on revenue growth and managing operational costs is essential for improving financial health.

Income Statement

The company shows a significant decline in revenue growth over the years, with TTM revenue at $19.1 million compared to $30 million in 2021. Gross profit margin is negative, indicating high operating costs. Net profit margin remains negative, reflecting ongoing losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and a lack of profitability.

Balance Sheet

The debt-to-equity ratio is low due to minimal debt, which is a positive aspect. However, the equity ratio has decreased over time, indicating a decline in financial stability. Return on equity is negative, reflecting persistent losses. The company maintains a strong cash position, although total assets have decreased, indicating potential liquidity concerns.

Cash Flow

The operating cash flow to net income ratio is negative, reflecting cash outflows from operations. Free cash flow has improved slightly but remains negative, indicating an inability to generate sufficient cash to cover expenses. Positive financing cash flow suggests reliance on external funding to support operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.00M	5.72M	1.66M	652.00K	30.02M	9.93M
Gross Profit	-865.00K	5.72M	-2.38M	652.00K	28.64M	-27.55M
EBITDA	-52.82M	-76.74M	-87.92M	-100.26M	-43.89M	-36.31M
Net Income	-54.90M	-75.41M	-87.30M	-101.94M	-44.97M	-36.60M
Balance Sheet
Total Assets	100.33M	91.05M	159.56M	205.32M	298.58M	348.99M
Cash, Cash Equivalents and Short-Term Investments	42.55M	72.99M	130.63M	161.28M	268.80M	335.45M
Total Debt	1.76M	3.41M	4.20M	4.90M	0.00	0.00
Total Liabilities	7.09M	11.42M	14.86M	29.17M	26.80M	39.13M
Stockholders Equity	93.24M	79.63M	144.71M	176.16M	271.79M	309.86M
Cash Flow
Free Cash Flow	-48.83M	-60.57M	-81.64M	-106.11M	-65.04M	-34.39M
Operating Cash Flow	-48.76M	-60.52M	-81.23M	-94.50M	-57.12M	-33.66M
Investing Cash Flow	3.11M	-8.51M	110.86M	49.44M	-10.44M	-146.32M
Financing Cash Flow	44.37M	787.00K	48.62M	171.00K	1.93M	330.87M

Shattuck Labs Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Positive. The current price of 3.14 is above the 20-day moving average (MA) of 2.73, above the 50-day MA of 2.25, and above the 200-day MA of 1.44, indicating a bullish trend. The MACD of 0.26 indicates Positive momentum. The RSI at 68.58 is Neutral, neither overbought nor oversold. The STOCH value of 35.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STTK.

Shattuck Labs Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STTK	54 Neutral	$199.33M	-3.08	-57.84%	―	-84.46%	33.32%
XLO	54 Neutral	$35.12M	-1.01	-908.28%	―	588.40%	61.76%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LVTX	44 Neutral	$42.75M	-1.54	-101.50%	―	-32.06%	16.38%
PYPD	41 Neutral	$63.11M	-1.33	-390.53%	―	―	61.23%
ACRV	36 Underperform	$68.16M	-1.09	-50.23%	―	―	21.17%

Shattuck Labs Corporate Events

Shattuck Labs’ SL-325 Phase 1 Trial: A Key Development in Biopharmaceuticals

Shattuck Labs, Inc. is conducting a Phase 1 clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers.’ The study aims to evaluate the safety and tolerability of SL-325, a DR3 blocking antibody, in healthy individuals. This research is significant as it represents the first human trial of SL-325, potentially paving the way for future therapeutic applications.

Shattuck Labs Closes $103M Private Placement Deal

On August 26, 2025, Shattuck Labs announced the closing of a private placement of up to $103 million, led by OrbiMed, which is expected to fund operations into 2029 and advance their lead program, SL-325, through multiple clinical milestones. The company also appointed Dr. Daniel Baker and Dr. Mona Ashiya to its Board of Directors, marking a strategic repositioning towards an immunology and inflammation-focused organization. These developments are significant as they aim to enhance Shattuck’s industry positioning and potentially improve outcomes for patients with immune-mediated diseases.

The most recent analyst rating on (STTK) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Shattuck Labs stock, see the STTK Stock Forecast page.

Shattuck Labs Reports Q2 2025 Financial Results

Shattuck Labs, Inc. is a biotechnology company based in Austin, Texas, specializing in developing treatments for inflammatory and immune-mediated diseases, with a focus on innovative antibody therapies. The company recently released its earnings report for the quarter ending June 30, 2025, highlighting significant financial figures and strategic developments. Shattuck Labs reported a net loss of $26.2 million for the first half of 2025, compared to a $40.1 million loss in the same period last year. The company’s research and development expenses decreased significantly, reflecting a strategic shift in its operational focus. Despite the financial losses, Shattuck Labs maintains a stable cash position with $50.5 million in cash and cash equivalents, sufficient to fund operations for the next twelve months. Looking forward, Shattuck Labs remains committed to advancing its clinical trials and product development, while navigating the challenges posed by the current economic environment.

Shattuck Labs Announces $103M Private Placement Funding

On August 5, 2025, Shattuck Labs announced an oversubscribed private placement expected to raise up to approximately $103 million, led by OrbiMed and other investors. The funds will support the clinical development of SL-325 through multiple Phase 2 trials for inflammatory bowel disease and potentially other autoimmune diseases, with operations funded into 2029. The private placement involves shares of common stock and pre-funded warrants, with the proceeds contingent on certain regulatory clearances and conditions.

The most recent analyst rating on (STTK) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Shattuck Labs stock, see the STTK Stock Forecast page.